Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00848289 · ClinicalTrials.gov registry record
Genetic Susceptibility to Bladder Cancer
A clinical trial of Bladder Cancer, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- 6,086
- Enrollment target
- 2
- Study locations
NCT00848289: Active study of Bladder Cancer, sponsored by M.D. Anderson Cancer Center.
NCT00848289 is a study of Bladder Cancer that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 6,086 participants, below the 12,719-participant average among 175 other Bladder Cancer trials with a reported enrollment target (52% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00848289, a study of Bladder Cancer, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 6,086 participants
- Enrollment target
- 2
- Study locations
Study Summary
This clinical research study will identify biologic and lifestyle factors which increase a person's risk of developing specific cancer. Researchers propose to conduct a case-control study examining interindividual differences in susceptibility to tobacco carcinogenesis as predictors of bladder cancer risk. We will measure susceptibility to tobacco carcinogenesis and this will include studies of the genetic modulation of carcinogen activation and detoxification and of chromosome sensitivity to tobacco mutagens.
Primary Outcome
Mutagen sensitivity as measured by quantifying the number of lymphocytic chromatid breaks and comet tail moments induced by in vitro exposure to bleomycin (a radiomimetic agent) and benzo\[a\]pyrene diol epoxide (BPDE, a tobacco carcinogen) in bladder cancer cases in comparison to data for controls
Conditions Studied
Interventions
- BEHAVIORAL Interviews
Study Locations (2)
Texas
- Baylor College of Medicine - Houston
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,086 participants |
| Start Date | 1998-02-10 |
| Est. Completion | 2026-08-01 |
What the registry record for NCT00848289 still lists
NCT00848289 is an observational study that tracks outcomes without assigning an intervention. Its 6,086 participants enrollment target places it among the larger protocols in the corpus, below the 12,719-participant average among 175 other Bladder Cancer trials with a reported enrollment target (52% lower).
The record links to 1 condition, with Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which Interviews is the first listed.
NCT00848289 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00848289 about?
NCT00848289 is a clinical study titled "Genetic Susceptibility to Bladder Cancer". This clinical research study will identify biologic and lifestyle factors which increase a person's risk of developing specific cancer. Researchers propose to conduct a case-control study examining interindividual differences in susceptibility to tobacco carcinogenesis as predictors of bladder cance...
What is the current status of trial NCT00848289?
This trial is currently active not recruiting. The enrollment target is 6,086 participants. The study started on 1998-02-10. Estimated completion is 2026-08-01.
What conditions does trial NCT00848289 study?
This clinical trial studies the following conditions: Bladder Cancer.
What interventions are being tested in trial NCT00848289?
The interventions under investigation include: Interviews (BEHAVIORAL).
Who is sponsoring clinical trial NCT00848289?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00848289 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00848289's enrollment target sits among peer trials
6,086 5th of 175 higher than 171 of 175 other Bladder Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
RECRUITING · NA
-
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
RECRUITING · Phase 1
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07166861 · 6,080 participants · NA
Annual Wellness Visits vs GRACE-augmented Annual Wellness Visits For Older Adults With High Needs - Phase 2
- NCT05884190 · 6,030 participants · NA
Trauma-informed Approach to Timely Detection and Management of Early Postpartum Hypertension
- NCT04774159 · 6,150 participants · Phase 3
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
- NCT06304168 · 6,150 participants
Validation of DNA Methylation Markers for Universal and Site-specific Guided Cancer Detection, VANGUARD Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI